Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?
Open Access
- 12 May 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (10) , 5115
Abstract
Melanoma is one of the most aggressive forms of skin cancer and is therapeutically challenging, considering its high mutation rate. Following the development of therapies to target BRAF, the most frequently found mutation in melanoma, promising therapeutic responses were observed. While mono- and combination therapies to target the MAPK cascade did induce a therapeutic response in BRAF-mutated melanomas, the development of resistance to MAPK-targeted therapies remains a challenge for a high proportion of patients. Resistance mechanisms are varied and can be categorised as intrinsic, acquired, and adaptive. RASSF1A is a tumour suppressor that plays an integral role in the maintenance of cellular homeostasis as a central signalling hub. RASSF1A tumour suppressor activity is commonly lost in melanoma, mainly by aberrant promoter hypermethylation. RASSF1A loss could be associated with several mechanisms of resistance to MAPK inhibition considering that most of the signalling pathways that RASSF1A controls are found to be altered targeted therapy resistant melanomas. Herein, we discuss resistance mechanisms in detail and the potential role for RASSF1A reactivation to re-sensitise BRAF mutant melanomas to therapy.Keywords
Funding Information
- Science Foundation Ireland (15/CDA/3495)
This publication has 171 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- A Landscape of Driver Mutations in MelanomaCell, 2012
- RASSF1A suppresses melanoma development by modulating apoptosis and cell‐cycle progressionJournal of Cellular Physiology, 2010
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Melanoma EpidemiologyHematology/Oncology Clinics of North America, 2009
- The tumour suppressor RASSF1A promotes MDM2 self‐ubiquitination by disrupting the MDM2–DAXX–HAUSP complexThe EMBO Journal, 2008
- RASSF1A Elicits Apoptosis through an MST2 Pathway Directing Proapoptotic Transcription by the p73 Tumor Suppressor ProteinMolecular Cell, 2007